Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06506656
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-01
Brief Title:
Hyaluronic Acid and Adelmidrol Hyadrol in Patients With Degenerative Joint Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Effect of an Intra-articular Treatment With a Combination of Hyaluronic Acid and Adelmidrol Hyadrol on Pain Joint Stiffness and Functional Limitation in Patients With Degenerative Joint Disease
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Osteoarthritis is a major cause of chronic musculoskeletal pain Behind this disorder there is a process of chronic neuroinflammation due to the overactivation of mast cells at the tissue level The mast cells present in the synovial membranes act as first sensors in pathological situations degranulating in an uncontrolled manner
Furthermore in degenerative joint pathologies there is a marked reduction in the viscoelastic capacity of the synovial fluid associated with a reduction in both the concentration and the average molecular weight of endogenous hyaluronic acid The association of hyaluronic acid and Adelmidrol Hyadrol could represent an effective treatment for controlling the neuroinflammation process that supports degenerative joint diseases
The objective of the present clinical investigation is to evaluate its safety and efficacy in patients with arthritis of the hip coxarthrosis and trapezium-metacarpal joints rhizoarthrosis
Furthermore in degenerative joint pathologies there is a marked reduction in the viscoelastic capacity of the synovial fluid associated with a reduction in both the concentration and the average molecular weight of endogenous hyaluronic acid The association of hyaluronic acid and Adelmidrol Hyadrol could represent an effective treatment for controlling the neuroinflammation process that supports degenerative joint diseases
The objective of the present clinical investigation is to evaluate its safety and efficacy in patients with arthritis of the hip coxarthrosis and trapezium-metacarpal joints rhizoarthrosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None